Skip to content
Back to Investors
E

Esperante

Venture Capital

Portfolio

2

companies

By category

  • HealthTech£2.5M
  • BioTech£2.0M

By location

  • Newcastle upon Tyne£2.5M
  • United Kingdom£2.0M

Portfolio companies

AB

AMLo Biosciences

AMLo Biosciences develops diagnostic tests to identify low-risk early-stage skin cancer.

U

UroSens

UroSens develops diagnostic immunoassays to detect prostate and bladder cancer.


Recent investments

Seed
£2.5M

Future Planet Capital led the round as the med-tech startup prepares for international market launches.

"This funding allows AMLo to embark on the next step of our journey with the resources to potentially relieve countless people with early-stage melanoma from the anxiety and follow-up burden that should be reserved for those with higher risk disease. I am delighted to welcome several new investors, and especially to see such strong additional commitment from our previous partners. Our levelling up from an academic spin-out to commercial success is critical to ensure we have the resources to further drive innovation in medical devices across our markets."
— Marie Labus, CEO and Co-founder